3.9300
-0.2400
(-5.76%)
At close: 3:04:03 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
6,202,989.4257
6,460,841.3155
6,350,025.8270
6,471,866.3350
5,845,621.5257
Cost of Revenue
5,095,905.7528
5,232,265.2134
5,133,065.3703
5,119,370.5988
4,593,543.5074
Gross Profit
1,107,083.6729
1,228,576.1020
1,216,960.4567
1,352,495.7362
1,252,078.0183
Operating Expense
719,917.6129
764,555.3333
836,448.1310
787,148.0638
802,121.3542
Operating Income
387,166.0600
464,020.7688
380,512.3257
565,347.6724
449,956.6641
Net Non Operating Interest Income Expense
-16,537.9131
-27,755.0084
-38,980.3021
-87,164.8815
-85,047.9309
Pretax Income
324,592.9269
396,021.5920
313,393.5524
421,124.7644
267,455.9282
Tax Provision
41,528.2822
42,249.0866
45,138.2726
47,169.7010
46,880.8735
Net Income Common Stockholders
217,247.3747
287,232.7989
224,374.0220
272,869.1877
173,521.4751
Basic EPS
0.12
0.15
0.12
0.15
0.11
Diluted EPS
0.12
0.15
0.12
0.15
0.11
Basic Average Shares
1,887,452.0000
1,914,885.3260
1,869,783.5170
1,819,127.9180
1,577,467.9550
Diluted Average Shares
1,887,452.0000
1,914,885.3260
1,869,783.5170
1,819,127.9180
1,577,467.9550
Total Operating Income as Reported
312,429.1181
385,033.1410
316,322.5067
451,510.1120
287,403.1215
Total Expenses
5,815,823.3657
5,996,820.5467
5,969,513.5013
5,906,518.6626
5,395,664.8616
Net Income from Continuing & Discontinued Operation
217,247.3747
287,232.7989
224,374.0220
272,869.1877
173,521.4751
Normalized Income
278,019.3218
341,396.2736
277,989.5791
300,034.4653
225,342.8944
Interest Income
10,146.0306
12,729.5966
13,539.2801
14,001.6659
15,366.9147
Interest Expense
25,902.7693
39,698.4229
51,787.6959
100,192.0878
99,614.5802
Net Interest Income
-16,537.9131
-27,755.0084
-38,980.3021
-87,164.8815
-85,047.9309
EBIT
350,495.6961
435,720.0150
365,181.2483
521,316.8522
367,070.5084
EBITDA
350,495.6961
672,430.3690
608,727.3321
768,647.2990
598,717.4327
Reconciled Cost of Revenue
5,095,905.7528
5,232,265.2134
5,133,065.3703
5,119,370.5988
4,593,543.5074
Reconciled Depreciation
--
236,710.3540
243,546.0838
247,330.4469
231,646.9243
Net Income from Continuing Operation Net Minority Interest
217,247.3747
287,232.7989
224,374.0220
272,869.1877
173,521.4751
Total Unusual Items Excluding Goodwill
-69,687.7711
-60,631.9178
-62,637.2383
-30,591.8337
-62,835.5090
Total Unusual Items
-69,687.7711
-60,631.9178
-62,637.2383
-30,591.8337
-62,835.5090
Normalized EBITDA
420,183.4672
733,062.2868
671,364.5704
799,239.1328
661,552.9417
Tax Rate for Calcs
0.0001
0.0001
0.0001
0.0001
0.0002
Tax Effect of Unusual Items
-8,915.8240
-6,468.4431
-9,021.6812
-3,426.5561
-11,014.0896
12/31/2020 - 4/16/2010
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
002370.SZ Zhejiang Yatai Pharmaceutical Co., Ltd.
3.2800
+0.31%
002437.SZ HARBIN GLORIA PHARMACEUTICALS Co., LTD
2.4900
-0.80%
600664.SS Harbin Pharmaceutical Group Co., Ltd.
3.7100
0.00%
TRILC.IS Turk Ilac Ve Serum Sanayi Anonim Sirketi
17.33
-1.53%
600518.SS Kangmei Pharmaceutical Co., Ltd.
2.2200
0.00%
600789.SS Shandong Lukang Pharmaceutical Co.,Ltd.
8.90
-0.45%
PYFA.JK PT Pyridam Farma Tbk
216.00
-1.82%